Company news

Shionogi & Co., Ltd. news in 2026

Shionogi & Co., Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Notice of Partial Correction to “Notice of Revisions to Earnings Forecasts and Dividend Forecasts (Dividend Increase)”

October 29, 2026

Notice Regarding Interim Dividend

October 29, 2026

Notice of Revisions to Earnings Forecasts and Dividend Forecasts (Dividend Increase)

October 28, 2026

Financial Results for the 2nd Quarter of FY2026 Supplement

October 28, 2026

Consolidated Financial Results for the Second Quarter of Fiscal Year 2026 (IFRS)

October 28, 2026

1st Half (Interim Period) of Fiscal 2026 Financial Results

October 28, 2026

D-Wave Customer Shionogi Wins First Place in NEDO Quantum Computing Challenge’s Quality of Life Category

October 28, 2026

Shionogi Continues Rare Disease Expansion With Planned Acquisition of IntraBio Inc.

October 5, 2026

COVGOZE for Intramuscular Injection (JN.1-adapted), Recombinant Protein COVID-19 Vaccine, Receives Partial Change Approval in Japan

September 16, 2026

Shionogi Announces U.S. Government Procurement of Fetroja through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats

August 31, 2026

Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats

August 28, 2026

Consolidated Financial Results for the First Quarter of Fiscal Year 2026 (IFRS)

August 3, 2026

Shionogi Recognizes the Four-Year Anniversary of RADICAVA ORS® (edaravone) for Treatment of ALS

July 30, 2026

Shionogi Announces U.S. Availability of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure*

July 28, 2026

Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan

July 23, 2026

Kirin Group and Blackmores to Launch New Cognizin® Cognitive Support Supplements in Australia and New Zealand

July 22, 2026

FDA Accepts Shionogi’s sNDA for Fetroja® (cefiderocol) for Use in Pediatric Patients with Serious Infections Caused by Susceptible Gram-negative Bacteria

July 16, 2026

Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan

June 24, 2026

Shionogi Announces Supplemental Approval in Japan for Pediatric Dosage and Administration of XOCOVA to Treat COVID-19

June 19, 2026

Positive Topline Results from Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome Followed by SOC in Patients with Invasive Aspergillosis

June 17, 2026

Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure

June 1, 2026

FY2025 Financial Results

May 12, 2026

FY2025 Supplement

May 12, 2026

Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats

April 8, 2026

ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-Producing Enterobacterales Infections

April 7, 2026

Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)

April 1, 2026

Apnimed Announces Strategic Monetization of Shionogi-Apnimed Sleep Science (SASS) Joint Venture Stake for $150M and Royalties, Strengthening Focus on its Wholly-Owned OSA Program, AD109

March 24, 2026

Shionogi & Co., Ltd. - ZURZUVAE Capsules 30 mg for the Treatment of Major Depressive Disorder launched in Japan

March 20, 2026

ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen

February 25, 2026

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing

February 25, 2026

ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026

February 17, 2026

Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd.

February 10, 2026

Shionogi Awarded the Minister of Health, Labour and Welfare Award for Cefiderocol at the 8th Japan Medical Research and Development Grand Prize

January 19, 2026

Decks in 2026